AB Science Successfully Completes €1.925 Million Private Placement
AB Science S.A. (the "Company" or "AB Science", Euronext – FR0010557264 – AB) has recently concluded a capital increase amounting to €1.925 million through a private placement, marking a significant step in its financial strategy. This funding was subscribed by a select group of investors, which provides the Company with necessary capital to advance its clinical projects.
Details of the Private Placement
The completed private placement is exempt from the requirement of a prospectus that needs approval from the French Financial Market Authority (AMF). Under specific EU regulations, AB Science has submitted pertinent information regarding this placement which will be readily accessible on the Company's website.
Utilization of Funds
The net proceeds from this private placement are aimed at financing ongoing operations, predominantly focusing on the clinical advancement of the AB8939 program. This strategic move reflects the Company's commitment to maintaining a robust cash position, which is essential for fulfilling its financial requirements in the near future.
Implications for Shareholders
This transaction has the potential to impact existing shareholders as it introduces 1,645,302 new ordinary shares into the market, along with attached share warrants known as BSA (bons de souscription d’actions). It is vital for current shareholders to understand that their stakes may be diluted as a result of this funding initiative.
Impact of the Private Placement
As a result of issuing these new shares, AB Science's total share capital is now approximately €681,937.55. Post-transaction, a shareholder who previously held 1.00% of the share capital will experience a reduction in their ownership to about 0.98%. However, this financial maneuver secures funds that will propel the Company towards future growth and innovation in therapeutic development.
Trading of New Shares
The new shares are projected to commence trading on the Euronext Paris market soon after the completion of the placement, following the established timeline set forth by the Company.
Future Expectations
Looking ahead, the issuance of new shares demonstrates confidence in the Company's ongoing projects, particularly the promising developments in the AB8939 program, which is of particular interest in oncological treatments.
AB Science has established itself within the pharmaceutical landscape by specializing in protein kinase inhibitors to tackle severe medical conditions with high unmet needs. The successful completion of this private placement signifies not only financial security but also a commitment to advancing vital treatments within the realm of human health.
Frequently Asked Questions
What was the amount raised in the private placement by AB Science?
AB Science successfully raised €1.925 million through its latest private placement.
What will the proceeds of the private placement be used for?
The funds will primarily support the clinical development of the AB8939 program and cover ongoing operational activities.
How many new shares were issued in this private placement?
A total of 1,645,302 new ordinary shares were issued as part of the private placement.
What are the effects of the private placement on existing shareholders?
Existing shareholders may face dilution of their ownership percentage due to the introduction of new shares.
When will the new shares begin trading?
The new shares are expected to begin trading on Euronext Paris shortly after the completion of the private placement.
